ArticleFrontiers in public health2021
Economic Evaluation of First-Line Camrelizumab for Advanced Non-small-cell Lung Cancer in China.
Article in Frontiers in public health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Sponsorship bias in published pharmacoeconomic evaluations of national reimbursement negotiation drugs in China: a systematic review.BMJ global health · 2023Pooled it
- Cost-effectiveness analysis of sugemalimab vs. placebo, in combination with chemotherapy, for treatment of first-line metastatic NSCLC in China.Frontiers in public health · 2022Trial
- Cost-effectiveness analysis based on two models of sacituzumab tirumotecan versus platinum-based chemotherapy as second-line treatment in EGFR-mutant non-small-cell lung cancer.Frontiers in public health · 2026Article
- Comparative cost-effectiveness of sintilimab, toripalimab, and camrelizumab in first-line therapy for advanced non-squamous non-small cell lung cancer.Frontiers in public health · 2025Article
- Cost-Effectiveness Analysis of Adjuvant Alectinib versus Platinum-Based Chemotherapy in Resected ALK-Positive Non-Small-Cell Lung Cancer in the Chinese Health Care System.Cancer medicine · 2024Article
- A multicenter, real-world study on effectiveness and safety of first-line modified PD-1 inhibitors with chemotherapy in advanced non-small cell lung cancer (aNSCLC) with drive gene-negative.Cancer medicine · 2024Article
- Cost-Effectiveness of First-Line Atezolizumab versus Chemotherapy in Non-Small-Cell Lung Cancer Patients Ineligible for Platinum-Containing Regimens.Risk management and healthcare policy · 2024Article
- Cost-effectiveness analysis of Tumor Treating Fields treatment in Chinese patients with metastatic non-small cell lung cancer.Frontiers in public health · 2024Article
- Cost-effectiveness analysis of adding durvalumab to chemotherapy as first-line treatment for advanced biliary tract cancer based on the TOPAZ-1 trial.Cost effectiveness and resource allocation : C/E · 2023Article
- The cost-effectiveness of cemiplimab plus chemotherapy as the first-line treatment for advanced non-small cell lung cancer.Frontiers in pharmacology · 2023Article
- Cost-effectiveness of camrelizumab plus chemotherapy vs. chemotherapy in the first-line treatment of non-squamous NSCLC: Evidence from China.Frontiers in medicine · 2023Article
- Economic evaluation of five first-line PD-(L)1 inhibitors for treating non-squamous non-small cell lung cancer in China: A cost-effectiveness analysis based on network meta-analysis.Frontiers in pharmacology · 2023Article
- Risk factors for postoperative pulmonary infection in patients with non-small cell lung cancer: analysis based on regression models and construction of a nomogram prediction model.American journal of translational research · 2023Article
- Cost-effectiveness analysis of toripalimab plus chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer in China.Frontiers in immunology · 2023Article
- Cost-effectiveness of serplulimab as first-line therapy for extensive-stage small cell lung cancer in China.Frontiers in immunology · 2023Article
- Cost-Utility Analysis of Camrelizumab Plus Chemotherapy Versus Chemotherapy Alone as a First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer in China.Frontiers in oncology · 2022Article
- Pathological complete remission in ALK-positive lung cancer patient after multiple lines of conversion therapy.Frontiers in oncology · 2022Article
- Emerging PD-1/PD-L1 targeting immunotherapy in non-small cell lung cancer: Current status and future perspective in Japan, US, EU, and China.Frontiers in oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.